News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 242780

Sunday, 11/15/2015 11:07:05 AM

Sunday, November 15, 2015 11:07:05 AM

Post# of 347009

Could have the late Dr. Andrew Parsa also been on the fast track to quickly learning re: PS Targeting ?

This becomes a little shocking. Now, Dr. Wolchok has been working with platforms from the late (both young..) Dr. Philip Thorpe / Dr. Andrew Parsa.



I think after many here have seen some of the publications of the late Andrew Parsa and his determination ( such as that of the late Dr. Philip Thorpe...) we could easily envision that Andrew Parsa would certainly have no problem in speaking honestly if he discovered the power of combination therapy with PS Targeting...

here is a video of the late Dr. Parsa- using own body's immune system:



...and remember, Agenus does have "unclassified.." work in their pipeline so they just may be another Peregrine collaborator, "ESPECIALLY" since we know see the facts that Dr. Jedd Wolchok was already working with Dr. Andrew Parsa... just as he is now working with Peregrine and the paradigm shifting technology of PS Targeting founded, discovered and advanced by the late Dr. Philip Thorpe

On those patents sit UTSWM / Peregrine CEO Steve King / Peregrine Pharmaceuticals / Troy Luster ..... and Alan Schroit on the early ones as well...

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y